What is Synklino?
Synklino is a Danish biotech enterprise spun out from the University of Copenhagen and the Technical University of Denmark, with incubation support from the BioInnovation Institute. The company is dedicated to creating groundbreaking treatments for cytomegalovirus (CMV), a pervasive viral infection that significantly increases hospital readmission rates and transplantation costs. Current therapeutic options for CMV are limited, lacking the potential for a cure and carrying the risk of developing resistance. Synklino's first-in-class drug candidate, SYN002, is specifically designed to combat CMV in transplant patients, aiming to revolutionize antiviral treatment paradigms and improve the quality of life for recipients.
How much funding has Synklino raised?
Synklino has raised a total of $48M across 1 funding round:
Series A
$48M
Series A (2022): $48M with participation from Eir Ventures, PKA pension fund, and The Danish Growth Fund
Key Investors in Synklino
Eir Ventures
Eir Ventures is a life science venture capital firm focused on financing the development of innovative medicine. With a seasoned investment team, they have made 20 investments, including 12 clinical programs and 2 products that have received marketing approval. The firm aims to drive Nordic innovation to enhance global health and deliver high returns for investors. Their investment strategy emphasizes transformative potential, excellence in execution, and scalability.
PKA pension fund
Undisclosed investor participating in the funding round.
The Danish Growth Fund
Undisclosed investor participating in the funding round.
What's next for Synklino?
With the recent major strategic investment, Synklino is positioned for significant advancement in its clinical development programs. The enterprise-level funding context suggests the company is moving towards later-stage development and potential commercialization. This capital infusion will likely be directed towards advancing SYN002 through further clinical trials, expanding its research and development capabilities, and potentially exploring strategic partnerships. The company's focus on a substantial unmet need in transplantation medicine indicates a strong market opportunity and a clear path for future growth and impact.
See full Synklino company page
